Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's disease (CD), that targets NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. It has several preclinical product candidates, including LABP-66, LABP-73 and LABP-69. LABP-73, an oral, small molecule NLRX1 agonist for the potential treatment of asthma and eosinophilic disorders.
LANDOS BIOPHARMA, INC. 
